Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
2.470
+0.160 (6.93%)
At close: Dec 20, 2024, 4:00 PM
2.480
+0.010 (0.40%)
After-hours: Dec 20, 2024, 7:54 PM EST
Sangamo Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for SGMO stock have an average target of 7.00, with a low estimate of 2.00 and a high estimate of 10. The average target predicts an increase of 183.40% from the current stock price of 2.47.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for SGMO stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 0 | 0 | 0 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 4 | 4 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +304.86% | Dec 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +304.86% | Dec 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +304.86% | Dec 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +304.86% | Nov 14, 2024 |
| Barclays | Barclays | Buy Maintains $3 → $9 | Buy | Maintains | $3 → $9 | +264.37% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
60.17M
from 176.23M
Decreased by -65.86%
Revenue Next Year
65.78M
from 60.17M
Increased by 9.31%
EPS This Year
-0.48
from -1.48
EPS Next Year
-0.21
from -0.48
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 71.3M | 108.2M | 193.8M | |||
| Avg | 60.2M | 65.8M | 106.6M | |||
| Low | 49.0M | 20.4M | 24.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -59.5% | 79.7% | 194.7% | |||
| Avg | -65.9% | 9.3% | 62.0% | |||
| Low | -72.2% | -66.1% | -62.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.42 | 0.58 | 0.11 |
| Avg | -0.48 | -0.21 | -0.18 |
| Low | -0.53 | -0.59 | -0.57 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.